ArcticZymes Technologies Valuation
Is B4V undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of B4V when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: B4V (€1.12) is trading below our estimate of fair value (€3.28)
Significantly Below Fair Value: B4V is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for B4V?
Key metric: As B4V is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is B4V's PE Ratio? | |
|---|---|
| PE Ratio | 146.8x |
| Earnings | NOK 4.63m |
| Market Cap | NOK 679.25m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4x |
| Enterprise Value/EBITDA | 594x |
| PEG Ratio | 1.8x |
Price to Earnings Ratio vs Peers
How does B4V's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17.8x | ||
2INV 2invest | 12.7x | n/a | €63.8m |
FYB Formycon | 12.9x | 31.5% | €827.2m |
BIO3 Biotest | 15.8x | 29.3% | €1.4b |
2FJ0 Pierrel | 29.9x | n/a | €92.8m |
B4V ArcticZymes Technologies | 146.8x | 80.1% | €679.2m |
Price-To-Earnings vs Peers: B4V is expensive based on its Price-To-Earnings Ratio (146.8x) compared to the peer average (17.8x).
Price to Earnings Ratio vs Industry
How does B4V's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: B4V is expensive based on its Price-To-Earnings Ratio (146.8x) compared to the European Biotechs industry average (27x).
Price to Earnings Ratio vs Fair Ratio
What is B4V's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 146.8x |
| Fair PE Ratio | 30.6x |
Price-To-Earnings vs Fair Ratio: B4V is expensive based on its Price-To-Earnings Ratio (146.8x) compared to the estimated Fair Price-To-Earnings Ratio (30.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.12 | €1.36 +21.3% | 6.2% | €1.45 | €1.28 | n/a | 2 |
| Oct ’25 | €1.49 | €2.09 +40.4% | 6.1% | €2.22 | €1.96 | n/a | 2 |
| Sep ’25 | €1.59 | €2.09 +31.7% | 6.1% | €2.22 | €1.96 | n/a | 2 |
| Aug ’25 | €2.16 | €2.33 +7.7% | 9.1% | €2.54 | €2.12 | n/a | 2 |
| Jul ’25 | €2.19 | €2.42 +10.7% | 9.1% | €2.64 | €2.20 | n/a | 2 |
| Jun ’25 | €2.08 | €2.38 +14.5% | 9.1% | €2.59 | €2.16 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Amneal Pharmaceuticals
US$2.6b
Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
2DT
US$7.70
7D
-4.3%
1Y
91.5%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$16.25
7D
2.5%
1Y
89.8%
Merck
US$252.6b
Operates as a healthcare company worldwide.
6MK
US$97.10
7D
6.7%
1Y
3.9%